1、 ERIK S S,PAUL D T,ALBERTO C,et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management[J]. Eur Heart J,2015,36(17): 1012-1022. ERIK S S,PAUL D T,ALBERTO C,et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management[J]. Eur Heart J,2015,36(17): 1012-1022.
2、 ROSENSON R S,BAKER S K,JACOBSON T A,et al. An assessment by the Statin Muscle Safety Task Force: 2014 update[J]. J ClinLipidol,2014,8(3):S58-71. ROSENSON R S,BAKER S K,JACOBSON T A,et al. An assessment by the Statin Muscle Safety Task Force: 2014 update[J]. J ClinLipidol,2014,8(3):S58-71.
3、 SANTOS P C,GAGLIARDI A C,MINAME M H,et al.SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgiain Brazilian patients with familial hypercholesterolemia[J]. Eur J ClinPharmacol,2012,68:273-279. SANTOS P C,GAGLIARDI A C,MINAME M H,et al.SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgiain Brazilian patients with familial hypercholesterolemia[J]. Eur J ClinPharmacol,2012,68:273-279.
4、 VOORA D,SHAH S H,SPASOJEVIC I,et al. TheSLCO1B1*5 genetic variant is associated with statin-induced side effects[J]. J Am CollCardiol,2009,54:1609-1616. VOORA D,SHAH S H,SPASOJEVIC I,et al. TheSLCO1B1*5 genetic variant is associated with statin-induced side effects[J]. J Am CollCardiol,2009,54:1609-1616.
5、 HPS2-THRIVE COLLABORATIVE GROUP. Effects of extended-release niacin with laropiprant in high-risk patients[J]. N Engl J Med,2014,371(3):203-212. HPS2-THRIVE COLLABORATIVE GROUP. Effects of extended-release niacin with laropiprant in high-risk patients[J]. N Engl J Med,2014,371(3):203-212.
6、 SAKAEDA T,KADOYAMA K,OKUNO Y,et al. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system[J]. Plos One,2011,6(12):e28124-e28124. SAKAEDA T,KADOYAMA K,OKUNO Y,et al. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system[J]. Plos One,2011,6(12):e28124-e28124.
7、 BRUCKERT E, HAYEM G, DEJAGER S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study[J]. Cardiovasc Drugs Ther,2005,19:403-414. BRUCKERT E, HAYEM G, DEJAGER S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study[J]. Cardiovasc Drugs Ther,2005,19:403-414.
8、 他汀类药物安全性评价工作组. 他汀类药物安全性评价专家共识[J]. 中华心血管病杂志,2014,42(11):279-293. 他汀类药物安全性评价工作组. 他汀类药物安全性评价专家共识[J]. 中华心血管病杂志,2014,42(11):279-293.
9、 FILIPPATOS T D, ELISAF M S. Safety considerations with fenofibrate/simvastatin combination[J]. Expert Opin Drug Saf,2015,14(9):1481-1493. FILIPPATOS T D, ELISAF M S. Safety considerations with fenofibrate/simvastatin combination[J]. Expert Opin Drug Saf,2015,14(9):1481-1493.
10、 ZHANG H, PLUTZKY J, SKENTZOS S, et al. Discontinuation of statins in routine care settings: a cohort study[J]. Ann Intern Med,2013,158:526-534. ZHANG H, PLUTZKY J, SKENTZOS S, et al. Discontinuation of statins in routine care settings: a cohort study[J]. Ann Intern Med,2013,158:526-534.
11、 中国成人血脂异常防治指南制定联合委员会.中国成人血脂异常防治指南[J]. 中华心血管病杂志,2007,35:390-419. 中国成人血脂异常防治指南制定联合委员会.中国成人血脂异常防治指南[J]. 中华心血管病杂志,2007,35:390-419.
